Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Widmer

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|August 15, 1997
Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorderM Bös, F Jenck, J R Martin, et al.
European Journal of Clinical Investigation|August 22, 2006
Hearing loss in Fabry disease: data from the Fabry Outcome SurveyS Hegemann, D Hajioff, G Conti, et al.
European Journal of Pharmacology|August 8, 1996
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activityJ Lundkvist, Z Chai, R Teheranian, et al.
Circulation|January 4, 2001
Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase inductionU Eriksson, M O Kurrer, R Bingisser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1997
C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitroK S Spanaus, D Nadal, H W Pfister, et al.
International Journal of Cardiology|November 26, 2005
Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophyPh Hoigné, C H Attenhofer Jost, F Duru, et al.
European Journal of Clinical Investigation|August 22, 2006
Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome SurveyD Hajioff, S Hegemann, S Hegemannn, et al.
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 21, 2008
Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapyT Kovacevic-Preradovic, M Zuber, C H Attenhofer Jost, et al.
Deutsche Medizinische Wochenschrift (1946)|July 4, 2007
[Fabry disease: demographic data since introduction of enzyme replacement therapy]M Cybulla, K Walter, H P Neumann, et al.
Mutation Research|January 28, 2003
Phototoxicity and photogenotoxicity of nine pyridone derivativesE Gocke, A A Chételat, M Csato, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|August 15, 1997
Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorderM Bös, F Jenck, J R Martin, et al.
European Journal of Clinical Investigation|August 22, 2006
Hearing loss in Fabry disease: data from the Fabry Outcome SurveyS Hegemann, D Hajioff, G Conti, et al.
European Journal of Pharmacology|August 8, 1996
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activityJ Lundkvist, Z Chai, R Teheranian, et al.
Circulation|January 4, 2001
Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase inductionU Eriksson, M O Kurrer, R Bingisser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1997
C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitroK S Spanaus, D Nadal, H W Pfister, et al.
International Journal of Cardiology|November 26, 2005
Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophyPh Hoigné, C H Attenhofer Jost, F Duru, et al.
European Journal of Clinical Investigation|August 22, 2006
Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome SurveyD Hajioff, S Hegemann, S Hegemannn, et al.
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 21, 2008
Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapyT Kovacevic-Preradovic, M Zuber, C H Attenhofer Jost, et al.
Deutsche Medizinische Wochenschrift (1946)|July 4, 2007
[Fabry disease: demographic data since introduction of enzyme replacement therapy]M Cybulla, K Walter, H P Neumann, et al.
Mutation Research|January 28, 2003
Phototoxicity and photogenotoxicity of nine pyridone derivativesE Gocke, A A Chételat, M Csato, et al.
Pageof 6